Medopad completes $25 million B round of financing

Nov. 6 (Xinhua) -- Mobile healthcare company Medopad announced the completion of a $25 million round of B financing. The round of funding is led by pharmaceutical giant Bayer, NWS Holdings and Healthbox.After this round of financing, Medopad's market value will exceed $200 million. In addition, Bayer will work with Medopad to develop digital biomarker diagnostics to improve human heart health.Since its establishment, Medopad has completed three financings with a total investment of US$54 million. The company completed a $1 million seed round in January 2016 and a $28 million A round in February 2018.Founded in 2008 and headquartered in London, UK, Medopad is a global mobile healthcare company with offices in the US and China. The company is committed to developing advanced diagnostic technologies to improve the quality of life of patients with chronic, rare and complex diseases. Medopad works with the world's leading healthcare, pharmaceutical and technology companies to create a connected digital healthcare ecosystem. (Arterial mesh)